C4 Therapeutics Inc

C4 Therapeutics Inc. a clinical-stage biopharmaceutical company develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer neurodegenerative conditions and other diseases. Its lead product candidate is CFT7455 an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634 an orally bioavailable BiDAC degrader of BRD9 a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946 an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma non-small cell lung cancer (NSCLC) colorectal cancer and other solid malignancies; CFT8919 an orally bioavailable allosteric and mutant-selective BiDAC degrader of epidermal growth factor receptor or EGFR with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown Massachusetts.